Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550254243> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2550254243 endingPage "406" @default.
- W2550254243 startingPage "398" @default.
- W2550254243 abstract "Fingolimod is a promising prodrug in attenuating multiple sclerosis and prolonging survival of organ allograft, with many other protective effects. Its mechanism of action is related to the internalization of sphingosine 1-phosphate receptors (S1PRs). Our previous study indicated that fingolimod eyedrops was efficacious in inhibiting ocular inflammation in a dry eye disease (DED) model of non-obese diabetic (NOD) mice. In the current study, we evaluated potential adverse effects of fingolimod eyedrops. Inbred 10-week-old BALB/c mice were randomly divided into four groups, fingolimod-treated groups at three different concentrations (0.01%, 0.1% and 0.5%) and a negative control group without intervention. Our results showed that in the 0.5% fingolimod group, adverse effects such as photophobia, catacleisis and corneal oedema were observed after 1 week of treatment. 1 month later, corneal opacity, oedema and neovascularization persisted till the mice were killed 2 months later. In contrast, there was no significant abnormality in the negative control group, and 0.01% and 0.1% fingolimod-treated groups. During a 2-month treatment period, we did not detect fingolimod, nor significant change in blood cells in peripheral blood, nor pathological changes in retina and systemic organs. Combined with our previous study and the current results, we recommend that an optimal range of safe and effective concentration of fingolimod as eyedrops is between 0.005% and 0.1%." @default.
- W2550254243 created "2016-11-30" @default.
- W2550254243 creator A5007811699 @default.
- W2550254243 creator A5044812188 @default.
- W2550254243 creator A5090394453 @default.
- W2550254243 creator A5090454827 @default.
- W2550254243 date "2017-01-22" @default.
- W2550254243 modified "2023-10-05" @default.
- W2550254243 title "Adverse Effect Profile of Topical Ocular Administration of Fingolimod for Treatment of Dry Eye Disease" @default.
- W2550254243 cites W1523354060 @default.
- W2550254243 cites W1582892440 @default.
- W2550254243 cites W1910269903 @default.
- W2550254243 cites W1983092575 @default.
- W2550254243 cites W1992656196 @default.
- W2550254243 cites W1994236211 @default.
- W2550254243 cites W2005104380 @default.
- W2550254243 cites W2010539762 @default.
- W2550254243 cites W2026202039 @default.
- W2550254243 cites W2033179866 @default.
- W2550254243 cites W2047564830 @default.
- W2550254243 cites W2055947480 @default.
- W2550254243 cites W2059921365 @default.
- W2550254243 cites W2072021875 @default.
- W2550254243 cites W2099738114 @default.
- W2550254243 cites W2106421222 @default.
- W2550254243 cites W2108813293 @default.
- W2550254243 cites W2123876964 @default.
- W2550254243 cites W2151340435 @default.
- W2550254243 cites W2154089780 @default.
- W2550254243 cites W2258921119 @default.
- W2550254243 cites W2282278488 @default.
- W2550254243 cites W2296153481 @default.
- W2550254243 cites W2324176144 @default.
- W2550254243 cites W2340948800 @default.
- W2550254243 cites W2735954633 @default.
- W2550254243 cites W918310856 @default.
- W2550254243 doi "https://doi.org/10.1111/bcpt.12717" @default.
- W2550254243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27888572" @default.
- W2550254243 hasPublicationYear "2017" @default.
- W2550254243 type Work @default.
- W2550254243 sameAs 2550254243 @default.
- W2550254243 citedByCount "2" @default.
- W2550254243 countsByYear W25502542432017 @default.
- W2550254243 countsByYear W25502542432022 @default.
- W2550254243 crossrefType "journal-article" @default.
- W2550254243 hasAuthorship W2550254243A5007811699 @default.
- W2550254243 hasAuthorship W2550254243A5044812188 @default.
- W2550254243 hasAuthorship W2550254243A5090394453 @default.
- W2550254243 hasAuthorship W2550254243A5090454827 @default.
- W2550254243 hasBestOaLocation W25502542431 @default.
- W2550254243 hasConcept C118487528 @default.
- W2550254243 hasConcept C126322002 @default.
- W2550254243 hasConcept C197934379 @default.
- W2550254243 hasConcept C203014093 @default.
- W2550254243 hasConcept C2776036978 @default.
- W2550254243 hasConcept C2780590625 @default.
- W2550254243 hasConcept C2780640218 @default.
- W2550254243 hasConcept C42219234 @default.
- W2550254243 hasConcept C71924100 @default.
- W2550254243 hasConcept C98274493 @default.
- W2550254243 hasConceptScore W2550254243C118487528 @default.
- W2550254243 hasConceptScore W2550254243C126322002 @default.
- W2550254243 hasConceptScore W2550254243C197934379 @default.
- W2550254243 hasConceptScore W2550254243C203014093 @default.
- W2550254243 hasConceptScore W2550254243C2776036978 @default.
- W2550254243 hasConceptScore W2550254243C2780590625 @default.
- W2550254243 hasConceptScore W2550254243C2780640218 @default.
- W2550254243 hasConceptScore W2550254243C42219234 @default.
- W2550254243 hasConceptScore W2550254243C71924100 @default.
- W2550254243 hasConceptScore W2550254243C98274493 @default.
- W2550254243 hasIssue "4" @default.
- W2550254243 hasLocation W25502542431 @default.
- W2550254243 hasLocation W25502542432 @default.
- W2550254243 hasOpenAccess W2550254243 @default.
- W2550254243 hasPrimaryLocation W25502542431 @default.
- W2550254243 hasRelatedWork W2079246512 @default.
- W2550254243 hasRelatedWork W2103925177 @default.
- W2550254243 hasRelatedWork W2260535563 @default.
- W2550254243 hasRelatedWork W2281794554 @default.
- W2550254243 hasRelatedWork W2327660953 @default.
- W2550254243 hasRelatedWork W2391832248 @default.
- W2550254243 hasRelatedWork W2401298936 @default.
- W2550254243 hasRelatedWork W2904853615 @default.
- W2550254243 hasRelatedWork W3025003623 @default.
- W2550254243 hasRelatedWork W3149632530 @default.
- W2550254243 hasVolume "120" @default.
- W2550254243 isParatext "false" @default.
- W2550254243 isRetracted "false" @default.
- W2550254243 magId "2550254243" @default.
- W2550254243 workType "article" @default.